SLC5A2 and hydrops fetalis: The EMPA-REG OUTCOME trial (Zinman et al., 2015), which evaluated the effects of SGLT2 inhibitors in patients with increased cardiovascular risk, showed significant reductions in all-cause mortality, HF hospitalization, and cardiovascular mortality.